Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in Hypertrophic Cardiomyopathy (MAVA-LTE)
NCT03723655Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2018
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Bristol Myers Squibb. Started Sep 2018; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT03723655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723655.